Generates Adjusted EBITDA of $3.6 million and EPS of $0.05 (CDN$0.61) Excluding legal provision EPS was $0.10 (CDN$0.12) OAKVILLE, ON, May 13, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. The company will hold...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has received approval from the Toronto Stock Exchange ("TSX") to amend its normal course issuer bid...

Adjusted EBITDA increases 9% to $13.7 million and EPS increases 60% to $0.16 (CDN$0.211) for the full year OAKVILLE, ON, March 18, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021. The company will hold...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has entered into an exclusive co-promotion agreement (the "Agreement") with Verity Pharmaceuticals Inc. for...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health...

Revenue Increases Sequentially to $4.9 million EBITDA2 was $2.7 million or 55% of net revenue OAKVILLE, ON, Nov. 12, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q3 2020 financial results after the close on Thursday, November 12, 2020. The Company will...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...